One of the most emotionally charged topics in reproductive medicine is also one of the most misunderstood. Patients who hear the words “recurrent implantation failure” often feel as if something is fundamentally broken. In most cases, the reality is far more hopeful — and far more statistically nuanced — than that diagnosis implies.
The natural limits of human fertility
Humans are naturally less fertile than most other species. If 100 couples aged 25 tried to conceive over a single month, only 25–30 would achieve a positive pregnancy test. Dogs, rabbits, and mice routinely achieve success rates of 60–95%. The main reason for our relative inefficiency is that we frequently produce chromosomally abnormal gametes, making multiple attempts not a sign of failure, but a normal part of the reproductive process.
This biological reality extends directly into assisted reproduction. Live birth rates per embryo transfer vary meaningfully by age: approximately 40–45% at age 30, around 35% at age 35, and closer to 20% at age 40. These are not poor outcomes — they reflect the underlying biology of human reproduction. With a 35% success rate per transfer, most individual attempts will statistically not succeed. That does not mean treatment is not working. It means persistence, and the right team, genuinely matter.
Is it really recurrent implantation failure?
The term “recurrent implantation failure” (RIF) carries enormous emotional weight — and it should not be applied carelessly after just two or three failed transfers. A premature diagnosis can lead patients and clinicians toward unnecessary strategy changes, avoidable expenditure on unproven add-ons, and a defeatist perspective that makes an already difficult journey harder.
The evidence is clear: most failed transfers have embryo-related causes, not uterine or immunological ones. Even when transferring PGT-A–confirmed euploid embryos — chromosomally normal embryos selected through genetic testing — implantation rates rarely exceed 60–70%. Several failed transfers, therefore, can fall well within normal expected statistical ranges and do not constitute a pathological condition.
What if I’ve already tried at another clinic?
Results vary enormously between fertility centers. An egg donation program achieving a 60% live birth rate is a fundamentally different experience than one achieving 30%. A failed treatment at another clinic does not predict the outcome of treatment here. The quality of the laboratory, the experience of the embryologist, the protocols used, and the materials and consumables chosen all have a measurable impact on outcomes. Success often comes down to executing standard protocols well — with the right team, in a quality laboratory, using appropriate materials.
What if it is true RIF?
When multiple transfers have failed under truly optimal conditions — confirmed euploid embryos, high-quality laboratory, experienced team — a deeper evaluation is warranted. True RIF is a diagnosis of exclusion, made after rigorous assessment rather than after a handful of unsuccessful attempts. Personalized medicine means adapting the approach based on the best available evidence for each individual patient, not simply trying every intervention that carries a theoretical rationale.
What evaluations might be considered?
- PGT-A: Preimplantation genetic testing reduces the risk of transferring chromosomally abnormal embryos and may shorten the path to a successful pregnancy.
- Endometrial assessment: Hysteroscopy and targeted biopsies can rule out chronic inflammation or infection. ERA (Endometrial Receptivity Analysis) may be offered in selected cases, though its clinical utility remains actively debated in the literature.
- Endometrial microbiome testing: Useful in selected cases; however, the evidence base remains limited and evolving.
- Donor gametes: Especially egg donation, when issues related to egg quality are suspected as the underlying cause of repeated failure.
What is not recommended: thrombophilia testing, natural killer (NK) cell analysis, immunology panels, and endometrial scratching lack support from rigorous clinical studies and are not endorsed by major international reproductive medicine guidelines. Offering these interventions prematurely adds cost and complexity without improving outcomes.
“Most patients concerned about implantation failure don’t actually have true RIF. Many fall within normal statistical ranges and simply need more attempts — with the right team.”
